Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fighting MDR G-Negative Infections

Published by예슬 탄 Modified over 5 years ago

Similar presentations

Presentation on theme: "Fighting MDR G-Negative Infections"— Presentation transcript:

1 Fighting MDR G-Negative Infections

2

3 What Is So Special About MDR GNB?

4 Resistance of CRE to Carbapenems

5 Classification and Characteristics of Major Carbapenemases in Enterobacteriaceae

6 Prevalence of Invasive CRE Infections Among Adult Patients in US Hospitals

7 Carbapenemase-Producing Enterobacteriaceae in the United States

8 Rise and Fall of KPC-Producing K Pneumoniae in New York City

9 Invasive K Pneumoniae Isolates With Resistance to Carbapenems, 2016

10 Prevalence of Carbapenem-Resistant K Pneumoniae in Different Provinces in China

11 Increasing Resistance of CRE K Pneumoniae in China

12 Reasons for the Increasing Prevalence of CRKP in China

13 CRE: Importance of Early and Effective Antibiotic Therapy

14 CRE Treatment and Assessment of Risk

15 Empiric Selection of Antibiotic Therapy

16 Selection of Empiric Therapy For Hospital-Acquired Infections

17 Importance of Local Epidemiology

18 Empirical Antibiotic Treatment Algorithm for HAP/VAP

19 Prediction Scores Studies for Certain ESKAPE Pathogens

20 CRE Infection: Combination Therapeutic Strategies

21 Treatment of CRE Infection in China: Challenges

22 KPC-2: Predominant Carbapenemase for CRKP in China

23 Treatment of CRE Infections in China

24 Ceftazidime-Avibactam: Clinical Considerations in Serious G-Negative Infections

25 Ceftazidime-Avibactam Treatment: Impact on Mortality

26 Meropenem-Vaborbactam: Clinical Considerations in Serious G-Negative Infections

27 TANGO II: Meropenem-Vaborbactam vs BAT in Patients With CR-Enterobacteriaceae Infections

28 Plazomicin: Clinical Considerations in Serious G-negative Infections

29 Plazomicin for Infections Caused by CRE: Results of the CARE Study

30 Eravacycline: Clinical Considerations in Serious G-Negative Infections

31 IGNITE 3: Eravacycline vs Ertapenem In cUTI

32 New Antibiotics in Development for the Treatment of CRE Infection

33 Features of a Successful Antibiotic Stewardship Program to Impact CRE

34 Program Summary

35 Abbreviations

36 Abbreviations (cont)

Download ppt "Fighting MDR G-Negative Infections"

Similar presentations

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.
Enoch Omonge University of Nairobi

Enoch Omonge University of Nairobi
Management of Neutropenic Fevers in cancer patients Jerry Yu.

Management of Neutropenic Fevers in cancer patients Jerry Yu.
H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.

H CAP & H AP Pamela Charity, MD Cathryn Caton, MD, MS.
Approach To Pneumonia. Pneumonia Importance Mechanism Classification & its benefit Diagnosis Treatment.

Approach To Pneumonia. Pneumonia Importance Mechanism Classification & its benefit Diagnosis Treatment.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.

Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
Carbapenemase- Producing Carbapenem-Resistant Enterobacteriaceae Nicole Hearon, HAI Epidemiologist Surveillance and Investigation Division Indiana State.

Carbapenemase- Producing Carbapenem-Resistant Enterobacteriaceae Nicole Hearon, HAI Epidemiologist Surveillance and Investigation Division Indiana State.
Infezioni invasive da Enterobacteriaceae Carbapenemico-Resistenti (CRE): da colonizzato a sepsi, quali fattori di rischio ? Roberto Luzzati Malattie Infettive,

Infezioni invasive da Enterobacteriaceae Carbapenemico-Resistenti (CRE): da colonizzato a sepsi, quali fattori di rischio ? Roberto Luzzati Malattie Infettive,
Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.

Antimicrobial resistance surveillance in Ireland Results of invasive Klebsiella pneumoniae infection (blood/CSF) surveillance, 2009 **** Data as of 01/12/2010.
Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,

Tigecycline use in serious nosocomial infections: a drug use evaluation Matteo Bassetti*, Laura Nicolini, Ernestina Repetto, Elda Righi, Valerio Del Bono,
1 Infectious Diseases in the Nursing Home Setting: Challenges and Opportunities for Clinical Investigation 감염내과 R2 김대호 / Prof. 이미숙 Manisha Juthani-Mehta.

1 Infectious Diseases in the Nursing Home Setting: Challenges and Opportunities for Clinical Investigation 감염내과 R2 김대호 / Prof. 이미숙 Manisha Juthani-Mehta.
Changing Epidemiology of Adult Bacterial Meningitis in Southern Taiwan: A Hospital-Based Study Infection 2008; 36: 15–22 W.-N. Chang, C.-H. Lu, C.-R. Huang,

Changing Epidemiology of Adult Bacterial Meningitis in Southern Taiwan: A Hospital-Based Study Infection 2008; 36: 15–22 W.-N. Chang, C.-H. Lu, C.-R. Huang,
Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;

Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;
HAP and VAP Guidelines Update

HAP and VAP Guidelines Update
Figure 1. Rate of antimicrobial resistance in S. pneumoniae

Figure 1. Rate of antimicrobial resistance in S. pneumoniae
Upfront Combination Therapy vs Step-Up Approach for PAH:

Upfront Combination Therapy vs Step-Up Approach for PAH:
Use of antibiotics.

Use of antibiotics.
Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.

Figure 1. Algorithm for classifying patients with hospital-acquired pneumonia according to the Consensus Statement of the American Thoracic Society. Adapted.
Background Goals Methods Conclusions Results

Background Goals Methods Conclusions Results
Professor Alan Johnson Department of HCAI & AMR

Professor Alan Johnson Department of HCAI & AMR

Similar presentations

Ads by Google